Madrigal Pharmaceuticals Q3 2024 GAAP EPS $(4.92) Beats $(6.92) Estimate, Sales $62.175M Beat $33.656M Estimate
Madrigal Pharmaceuticals, Inc. -1.17%
Madrigal Pharmaceuticals, Inc. MDGL | 350.70 | -1.17% |
Madrigal Pharmaceuticals (NASDAQ:
MDGL) reported quarterly losses of $(4.92) per share which beat the analyst consensus estimate of $(6.92) by 28.9 percent. The company reported quarterly sales of $62.175 million which beat the analyst consensus estimate of $33.656 million by 84.74 percent.